CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 10 enrolled
Drug / intervention
Carfilzomib +2 moredrug
Likely dose
Carfilzomib 2 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02545907
NCT02545907Phase 2Completed
CompareCT.gov

A Single Arm Open Labeled Multicentre Phase 1b Dose Escalation Study of Carfilzomib Taken in Combination With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis

University College, London·interventional·Posted Sep 10, 2015·Updated Apr 15, 2021

In Brief

A Phase 2 clinical trial evaluating Carfilzomib, Thalidomide, and 1 other intervention for Amyloidosis. Completed, enrolled 10 participants across 14 sites.

Detailed Summary

This study evaluates the safety and efficacy of carfilzomib used in combination with thalidomide and dexamethasone in patients with relapsed AL amyloidosis. The trial begins with a dose escalation phase, in which the maximum tolerated and recommended dose will be determined. The trial will then open into an expansion phase in which the combination efficacy is assessed.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAmyloidosis
CountriesUnited Kingdom
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 10, 2015
Enrollment StartSep 14, 2017
Primary CompletionSep 26, 2019
Study CompletionOct 21, 2019
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 10.8 years ago

Interventions

Carfilzomibdrug

Lyophilized carfilzomib for injection reconstituted with water to a final concentration of 2 mg/mL.

Thalidomidedrug

50mg capsule.

Dexamethasonedrug

2mg tablet.